Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
mHSPC
Advertisement
Latest News
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Drs. Swami and Ciuro discuss adoption of treatment intensification, barriers to guideline-concordant care, and more in mHSPC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.